A Biomarker Assessment System to Guide Pharmacotherapy
When treating patients with treatment-resistant neurobehavioral disorders, medication selection using objective physiologic data can add information of value to the physician’s development of an effective treatment plan.
CNS Response is the first company to create a biomarker database that predicts a patient’s response to major drug classes and to specific medications based on their individual brain functions. CNS Response developed this tool to improve pharmacotherapy outcomes in treatment-refractory patients, a particularly expensive patient population with profound unmet clinical needs.
The rEEG® process begins with standardized, FDA approved EEG equipment and data collection procedures. To produce the rEEG® report, CNSR compares un-medicated patients’ Quantitative EEG (QEEG) findings to a widely accepted national QEEG database of non-symptomatic people to evaluate brain functioning and to quantify their electro-physiologic abnormalities. Each patient’s QEEG is then compared for pattern recognition to CNSR’s proprietary database of medication-free patients whose rEEG® biomarkers were correlated with long-term medication outcomes.
A patient’s rEEG® findings are presented in a brief two-page report that identifies the patient’s response probability to major drug classes and specific medications based on the response rates of patients with similar electro-physiologic patterns. The rEEG® report is not diagnostic, but rather similar in format and use to an antibiotic sensitivity lab report thereby providing psychiatrists and other physicians with additional information to enhance their pharmacotherapy selection process.
Click here to learn more about becoming an rEEG Prescriber |
|
> Physicians Introductory Guide to rEEG
> EEG Techs Introductory Guide to rEEG
> rEEG Requisition Form
> Medication Half Life Detox Table
> Prescriber Portal Login |
